Fosun Pharma Launches Saladax's MyCare Dosing Assays in China

Shanghai Fosun Pharma's diagnostics subsidiary announced the China launch of the MyCare assay tests, which were developed by Saladax Biomedical of the US. The MyCare assays determine optimal chemotherapy dosing based on an individual patient's absorption and clearance rates. In March 2013, Fosun bought $22.4 million of Saladax's D shares, a deal that included China rights to the MyCare assays and gave Fosun majority ownership of Saladax. More details.... Stock Symbols: (SHA: 600196; HK: 02196) Share this with colleagues: // //